Radisens Diagnostics has announced a licensing deal with Tecan Trading AG., securing rights to Tecan’s industry leading centrifugal microfluidic patent portfolio. The licensed technology consists of a wide range of fundamental centrifugal microfluidic processes and structures which enable automated fluid processing of small sample volumes including valving, metering and mixing. Also covered are specific applications including affinity-binding based assays and enzymatic assays.
Jerry O’Brien, CEO Radisens Diagnostics said, “Tecan’s significant IP portfolio of granted patents cover novel and pioneering centrifugal microfluidic technologies, enabling Radisens to integrate multiple chronic and acute blood tests at the advanced performance and cost targets required at point-of-care”.
In related news, Dr. Greg Kellogg has joined Radisens Diagnostics as Product Development Director and Boston Office Manager. Greg is an internationally recognised pioneer of centrifugal microfluidics with a proven track record of innovative technology development and has built innovative R&D organizations while at Gamera, Tecan, Network Biosystems and Protiveris. Throughout his career, he has developed novel microfluidic technologies with applications in clinical and molecular diagnostics, genotyping, drug discovery and forensics, developing disposables, instrumentation and reagent products.
About Radisens Diagnostics
Radisens Diagnostics develops disruptive point-of-care diagnostic platforms and multiplexed test panels, which diagnose and monitor patients for multiple chronic and acute care conditions. This is the only point-of-care platform to integrate immunoassay, biochemistry and cellular haematology onto a single test panel. Using a finger-prick of blood, the analyser returns laboratory-grade results in the doctor’s office within minutes. With offices in the Rubicon Centre Cork, Ireland and Boston, Massachusetts, Radisens Diagnostics is a convergence of medical diagnostics and consumer electronics using disruptive patent pending technology to deliver on the significant market and clinical need for decentralising diagnostics into point of care settings such as doctor’s offices, outpatient and emergency room departments, intensive care units and hospital bedsides.
Commercial contact:
Jerry O’Brien
Radisens Diagnostics Ltd
E: info @ radisens.com
T: +353 21 4868190
